Synchronous Bilateral Shamblin Type III Carotid Body Tumors and Adrenal Pheochromocytoma with SDHD Mutation: A Rare Presentation, with Multimodality Imaging Findings

Abstract

Pheochromocytomas and paragangliomas are relatively rare tumors, with an incidence of approximately 0.6 cases per 100,000 person-years. Moreover, the co-occurrence of these tumors is extremely rare and is often associated with pheochromocytomas/paragangliomas-related pathogenic mutations. We present the case of a 33-year-old female diagnosed with bilateral carotid body paragangliomas and a concurrently detected pheochromocytoma, with metastases to the abdominal lymph nodes and lung. DNA analysis revealed a mutation in the succinate dehydrogenase subunit D gene. The tumors displayed high-grade SSTR expression (Krenning grade 4 uptake) on Gallium-68 [⁶⁸Ga]-DOTA-(Tyr³)-octreotate Positron Emission Tomography/Computed Tomography, with no significant tracer concentration on the I-131 MIBG scan. Another notable feature in this case was the visually evident intra- and inter-tumoral metabolic heterogeneity on ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography, especially within the multiple carotid paragangliomas. With the adoption of a multimodality diagnostic approach (MRI, FDG PET/CT, SSTR PET/CT, and I-131 MIBG scintigraphy), a holistic theranostic approach was employed with the most rational therapeutic option offered to the patient.

Keywords

carotid body tumors - PET/CT - ¹⁸F-FDG - ⁶⁸Ga-DOTATATE - ¹³¹I-MIBG - pheochromocytoma - Ki-67 - histopathological analysis

Publikationsverlauf

Artikel online veröffentlicht:
05. Januar 2026

• References

• 1 Neumann HPH, Young Jr WF, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med 2019; 381 (06) 552-565
• 2 Tzikos G, Menni A, Cheva A. et al. Composite paraganglioma of the celiac trunk: a case report and a comprehensive review of the literature. Front Surg 2022; 9: 824076
• 3 Aygun N, Uludag M. Pheochromocytoma and paraganglioma: from clinical findings to diagnosis. Sisli Etfal Hastan Tip Bul 2020; 54 (03) 271-280
• 4 Ilias I, Chen CC, Carrasquillo JA. et al. Comparison of 6 different PET tracers for the localization of pheochromocytoma. J Nucl Med 2008; 49 (10) 1613-1619
• 5 Han EJ, Lee SH, Song IU, Chung YA, Maeng LS. Simultaneous adrenal pheochromocytoma and carotid body paraganglioma in a woman. Nucl Med Mol Imaging 2013; 47 (01) 67-68
• 6 Thelen J, Bhatt AA. Multimodality imaging of paragangliomas of the head and neck. Insights Imaging 2019; 10 (01) 29
• 7 Janssen I, Chen CC, Taieb D. et al. 68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared to other functional imaging modalities and CT/MRI. J Nucl Med 2016; 57 (02) 186-191
• 8 Taïeb D, Timmers HJLM, Hindié E. et al; European Association of Nuclear Medicine. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2012; 39 (12) 1977-1995
• 9 Ilias I, Divgi C, Pacak K. Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer. Semin Nucl Med 2011; 41 (05) 364-368
• 10 Gupta G, Pacak K. AACE Adrenal Scientific Committee. Precision medicine: an update on genotype/biochemical phenotype relationships in pheochromocytoma/paraganglioma patients. Endocr Pract 2017; 23 (06) 690-704
• 11 Andrews KA, Ascher DB, Pires DEV. et al. Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD . J Med Genet 2018; 55 (06) 384-394
• 12 Lenders JW, Duh QY, Eisenhofer G. et al; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99 (06) 1915-1942
• 13 Robertson V, Poli F, Hobson B, Saratzis A, Ross Naylor A. A systematic review and meta-analysis of the presentation and surgical management of patients with carotid body tumours. Eur J Vasc Endovasc Surg 2019; 57 (04) 477-486
• 14 Basu S, Abhyankar A, Jatale P. The current place and indications of 131I-metaiodobenzylguanidine therapy in the era of peptide receptor radionuclide therapy: determinants to consider for evolving the best practice and envisioning a personalized approach. Nucl Med Commun 2015; 36 (01) 1-7
• 15 Brewczyński A, Kolasińska-Ćwikła A, Jabłońska B, Wyrwicz L. Pheochromocytomas and paragangliomas—current management. Cancers (Basel) 2025; 17 (06) 1029